Navigation Links
Novavax to Present Phase I/IIa Trial Data Results in an Investor Conference Call on August 26, 2008
Date:8/21/2008

com and in the Company's various filings with the Securities and Exchange Commission.

Forward Looking Statements

Statements herein relating to future development results and performance, conditions or strategies and other matters, including expectations regarding product and clinical developments are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including risks relating to the early stage of Novavax's product candidates under development; current results may not be predictive of future pandemic results, results of our seasonal influenza vaccine or any other vaccine that we may develop; further testing is required before FDA can be applied for and the FDA may not approve the pandemic vaccine even if further trial results are similar to those disclosed herein; uncertainties relating to clinical trials; dependence on the efforts of third parties; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; and risks that we may lack the financial resources and access to capital to fund our operations including further clinical trials. Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov. These forward-looking statements speak only as of the date of this press release, and Novavax assumes no duty to update forward-looking statements.


'/>"/>
SOURCE Novavax, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Novavax Announces Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine Development
2. Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial
3. Novavax Reports Positive Results from Preclinical Studies of its VLP-based Trivalent Seasonal Influenza Vaccine Candidate
4. Novavax Reports Fourth Quarter and 2007 Year-End Financial Results
5. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
6. Novavax Announces Preclinical Results for Seasonal Influenza Vaccine Program
7. GE Healthcare and Novavax Establish Collaboration To Develop and Market Pandemic Influenza Solution
8. Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs
9. Novavax CEO to Present at ACUMENBioFins 9th Annual Healthcare Conference
10. Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome)
11. Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 2014   LabStyle Innovations Corp . (OTCQB: ... today announced that it has closed a $4.2 ... preferred stock and warrants.  No placement agent was ... LabStyle expects to secure net proceeds of approximately ... LabStyle intends to use the net proceeds from ...
(Date:9/23/2014)... MINNETONKA, Minn. , Sept. 23, 2014   MedNet ... clinical study management systems, is pleased to announce that it ... for Clinical Data Management (SCDM) Annual Conference, to be held ... Las Vegas , Nevada. MedNet team members, in conjunction ... Partner Organizations who will also be in attendance, will ...
(Date:9/23/2014)... ORLANDO, Fla. and DUBLIN ... Inc. (OTC-BB: TNIB) ("we" or the "Company"), a ... innovative therapies for autoimmune diseases in emerging nations, ... has approved our common stock for DTC,s Deposit ... Fast Automated Securities Transfer Service ("FAST") transfer agent ...
Breaking Medicine Technology:LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing 2LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing 3LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing 4LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing 5MedNet Solutions - Proud To Sponsor The SCDM 2014 Annual Conference 2TNI BioTech, Inc. Announces Its Stock is Now DTC DWAC/FAST Eligible 2TNI BioTech, Inc. Announces Its Stock is Now DTC DWAC/FAST Eligible 3TNI BioTech, Inc. Announces Its Stock is Now DTC DWAC/FAST Eligible 4
... Reports on 11 Patients at SAWCPRINCETON, N.J., April 29 ... (OTC Bulletin Board: DSCI), a provider of advanced ... on the Advances in Wound Care (SAWC) in Dallas, Jason ... South Florida, revealed details of a recently concluded 11-patient venous ...
... the REDUCE trial results at the American Urological Association annual ... as dutasteride (Avodart), a drug used to treat benign prostatic ... of prostate cancer in men with an increased risk of ... an additional tool in the fight against prostate cancer. ...
Cached Medicine Technology:Clinician Reports Fast Healing of Intractable Wounds Using MEDIHONEY(R) 2Clinician Reports Fast Healing of Intractable Wounds Using MEDIHONEY(R) 3Study Results Present Paradigm Shift; REDUCE Trial Shows New Hope for the Risk Reduction of Prostate Cancer 2
(Date:9/23/2014)... York, NY (PRWEB) September 23, 2014 ... a moderate rate over the past five years. Growth ... health consciousness has encouraged Canadians to consume more fish ... has encouraged food retailers and food-service establishments to increase ... increasing industry revenue. Additionally, strong economic growth in much ...
(Date:9/23/2014)... 2014 Oaksterdam University has begun publishing ... its first post, the University addresses the need for ... industry. , The cannabis industry is becoming big business. ... an 18-month boost of more than $600 million in ... sales. And, the new legal recreational marijuana market in ...
(Date:9/23/2014)... "The primary purpose of the CALL LIGHT ... from Sacramento, Ca.. "Call lights are often found on the ... the IV pole out of the patient's reach. In order ... whenever they need it, I created this caddy." , She ... call device within easy reach. The accessory ensures that the ...
(Date:9/23/2014)... California, Davis, and Academia Sinica, the preeminent academic ... entered into a collaborative agreement to develop a ... cutting-edge research with opportunities to translate innovative technologies ... The agreement was signed Sept.12 in Taipei by ... Davis and President Chi-Huey Wong of Academia Sinica. ...
(Date:9/23/2014)... September 23, 2014 AttorneyOne.com, a recognized ... the latest information from the FDA on Jalapeno ... that its Private Label Jalapeno Bagels are recalled as ... Publix Jalapeno Bagels were sold in the ... , Taking into consideration the latest developments, AttorneyOne.com ...
Breaking Medicine News(10 mins):Health News:Fish and Seafood Wholesaling in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Fish and Seafood Wholesaling in Canada Industry Market Research Report Now Available from IBISWorld 3Health News:Oaksterdam University Addresses "Why Quality Training Matters in a Growing Marijuana Industry" in First Blog Post 2Health News:Oaksterdam University Addresses "Why Quality Training Matters in a Growing Marijuana Industry" in First Blog Post 3Health News:Academia Sinica, UC Davis sign agreement on exchanges and tech transfer 2Health News:Publix Private Label Jalapeno Bagels Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2
... CellCyte Genetics Corporation (CellCyte) (OTC Bulletin Board: ... published by the Seattle Times reporting ... incorrectly reported that CellCyte ,closes.,In CellCyte,s August 14, ... its bioreactor business segment and generally described its ...
... Dec. 29 Watson Pharmaceuticals,Inc. (NYSE: ... branded pharmaceuticals,today announced that its subsidiary, Watson Laboratories, ... Food and Drug Administration on its,Abbreviated New Drug ... USP, 0.15 mg / 0.02 mg. Desogestrel/ethinyl,estradiol ...
... Priority ReviewEAST BRUNSWICK, N.J., Dec. 29 Savient ... announced that the U.S. Food and Drug Administration ... License Application (BLA) for pegloticase, a novel biological ... also granted the Company,s BLA with a priority ...
... Cross and Blue Shield of Oklahoma announced today the ... their next policy year. This change will not in ... always been available to children with autism. Blue Cross ... interests in the benefits and coverage of certain autism-related ...
... Dec. 29 Eastern Life & Health Insurance Company (ELH), ... EIHI ), announced today that it will add vision to ... include a vision insurance plan and a vision discount program, ... "Adding vision to ELH,s product portfolio enables employers to offer ...
... 29 Life for Relief and Development (LIFE), a ... the civilian victims of the recent conflict in Gaza. ... non-governmental organizations operating in the area, LIFE has obtained ... relief items to Gaza via a specially designated humanitarian ...
Cached Medicine News:Health News:CellCyte Genetics Corporation: Seattle Times Erroneously Reports That CellCyte 'Closes' 2Health News:CellCyte Genetics Corporation: Seattle Times Erroneously Reports That CellCyte 'Closes' 3Health News:CellCyte Genetics Corporation: Seattle Times Erroneously Reports That CellCyte 'Closes' 4Health News:CellCyte Genetics Corporation: Seattle Times Erroneously Reports That CellCyte 'Closes' 5Health News:Watson Pharmaceuticals Receives FDA Final Approval for Generic Mircette(R) 2Health News:Pegloticase BLA Filing Accepted for Priority Review by FDA 2Health News:Pegloticase BLA Filing Accepted for Priority Review by FDA 3Health News:Pegloticase BLA Filing Accepted for Priority Review by FDA 4Health News:Blue Cross and Blue Shield of Oklahoma Announces Autism Benefits 2Health News:Eastern Life & Health Introduces New Vision Product 2Health News:Eastern Life & Health Introduces New Vision Product 3
... workmanship are the hallmark of these stereozoom ... mind. The top (incident) circular 9W fluorescent ... while remaining cool to the touch. Binocular ... 10x to 44x zoom magnification or high-power ...
... system expandability: the first inverted microscope to ... infinity space. Multi-port design enables optical input/output ... variety of illumination and detector equipment. Extendable ... an optional light source and other attachments ...
... Megapixel color imaging camera system designed ... high performance, megapixel digital cameras provides ... view them on a PC via ... This "live" previewing capability is accompanied ...
... camera with direct digital output. Three-chip color ... Olympus wide array of high-quality color video ... and flexibility you need for an efficient ... high-resolution, real-time image of your specimen that ...
Medicine Products: